natgillin/translations-raw huggingface dataset:
Parametrene for capecitabin, 5'-deoxy-5-fluorocytidin (5'-DFCR) og 5'-deoxy-5-fluorouridin (5'-DFUR) var ens på dag 1 og 14.
The parameters of capecitabine, 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouridine (5'-DFUR) measured on days 1 and 14 were similar.
Efter oral administration absorberes capecitabin hurtigt og fuldstændigt efterfulgt af en omfattende omdannelse til metabolitterne 5'-DFCR og 5‘-DFUR.
After oral administration, capecitabine is rapidly and extensively absorbed, followed by extensive conversion to the metabolites, 5'-DFCR and 5'-DFUR.
Patienter med lav eller manglende aktivitet af DPD, et enzym, der er involveret i nedbrydningen af fluoruracil, har en højere risiko for svære, livstruende eller dødelige bivirkninger forårsaget af fluoruracil.
Patients with low or absent DPD activity, an enzyme involved in fluorouracil degradation, are at increased risk for severe, life-threatening, or fatal adverse reactions caused by fluorouracil.
Da sikkerheds- og effektdata er baseret på administration sammen med maden anbefales det at tage capecitabin sammen med et måltid.
Since current safety and efficacy data are based upon administration with food, it is recommended that capecitabine be administered with food.
Andre bivirkninger, der kan ses i den sammenhæng er:
Other side-effects seen in this setting are the following:
I reproduktionstoksicitetsundersøgelser på dyr forårsagede administration af capecitabin embryoletalitet og teratogenicitet.
In reproductive toxicity studies in animals, capecitabine administration caused embryolethality and teratogenicity.
Administration sammen med føde nedsætter hastigheden af capecitabinabsorptionen, men medfører kun mindre virkning på 5‘-DFURs AUC og på AUC af den efterfølgende metabolit 5-FU.
Administration with food decreases the rate of capecitabine absorption, but only results in a minor effect on the AUC of 5'-DFUR, and on the AUC of the subsequent metabolite 5-FU.
Ecansya fås i blister (aluminium-aluminium eller PVC/PVdC-aluminium) indeholdende 30, 60 eller 120 filmovertrukne tabletter.
Ecansya is available in blisters (Aluminium-aluminium or PVC/PVdC-aluminium) containing 30, 60 or 120 film-coated tablets.
Det er ukendt, om capecitabin udskilles i human mælk.
It is not known whether capecitabine is excreted in human breast milk.
Hæmatologi Patienter, som ved baseline har et neutrofiltal < 1,5 x 10
Haematology Patients with baseline neutrophil counts of <1.5 x 10
Der findes ingen farmakokinetiske data om patienter med svær leverinsufficiens.
There are no pharmacokinetic data on patients with severe hepatic impairment.
9/l, bør ikke behandles med capecitabin.
9/L should not be treated with capecitabine.
Capecitabin har også været anvendt i kombination med oxaliplatin til behandling af fremskreden ventrikelkræft.
Capecitabine has also been used in combination with oxaliplatin for the treatment of advanced gastric cancer.
En effektiv præventionsmetode skal bruges under behandling og i 6 måneder efter sidste dosis af capecitabin.
An effective method of contraception should be used during treatment and for 6 months after the last dose of capecitabine.
Fuld dosis
Full dose
XELOX eller XELOX+ Bevacizumab
XELOX or XELOX+ Bevacizumab
I tilfælde af utilsigtet administration af brivudin til patienter, der behandles med capecitabin, bør der tages effektive foranstaltninger for at reducere toksiciteten af capecitabin.
In the event of accidental administration of brivudine to patients being treated with capecitabine, effective measures should be taken to reduce the toxicity of capecitabine.
Den mediane samlede overlevelse var 10,0 måneder for de cisplatinbaserede regimer og 10,4 måneder for de oxaliplatin-baserede regimer.
The median overall survival was 10.0 months in cisplatin-based regimens and 10.4 months in oxaliplatin-based regimens.
Effektdata er baseret på en gennemsnitlig observationstid på 59 måneder for samlet overlevelse og 57 måneder for sygdomsfri overlevelse.
The efficacy data is based on a median observation time of 59 months for OS and 57 months for DFS.
MINDSTEKRAV TIL MÆRKNING PÅ BLISTERKORT ELLER BLISTERSTRIPS BLISTER
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER
MARKEDSFØRINGSTILLADELSESNUMMER (NUMRE)
MARKETING AUTHORISATION NUMBER (S)
Der forekom ingen signifikant forskel i eksponeringen af andre metabolitter (5´-DFCR, 5´-DFUR og 5-FU).
No significant differences occurred in the exposure to other metabolites (5'-DFCR, 5'-DFUR, and 5-FU).
En sammenligning af XELOX plus bevacizumab versus FOLFOX-4 plus bevacizumab var en præspecificeret eksplorativ analyse.
A comparison of XELOX plus bevacizumab versus FOLFOX-4 plus bevacizumab was a pre-specified exploratory analysis.
Der er ingen data fra anvendelse af capecitabin til gravide kvinder, men det antages imidlertid, at capecitabin kan forårsage føtale skader, hvis det gives til gravide.
There are no studies in pregnant women using capecitabine; however, it should be assumed that capecitabine may cause foetal harm if administered to pregnant women.
Kun når det er optaget i kroppen ændres det til et aktivt anti-cancer stof (fortrinsvis i svulstvæv).
Only after being absorbed by the body is it changed into an active anti-cancer medicine (more in tumour tissue than in normal tissue).
For doseringen af XELOX og FOLFOX-4 (uden tillæg af placebo eller bevacizumab) se tabel 6.
For the dosing schedule of XELOX and FOLFOX-4 (without addition of placebo or bevacizumab), refer to table 6.
Alle grader
All grades
De pivotale Ecansya-studier inkluderede kun kvinder i den fertile alder og mænd, hvis de indgik i en aftale om at anvende en egnet præventionsmetode for at undgå graviditet under studiet og i en passende periode efter studiet.
The Ecansya pivotal studies included females of childbearing potential and males only if they agreed to use an acceptable method of birth control to avoid pregnancy for the duration of the study and for a reasonable period thereafter.
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE YDRE KARTON
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON
I studiet publiceret af Skof et al blev patienterne randomiseret til enten at få FOLFIRI eller XELIRI.
In the study published by Skof et al, patients were randomised to receive either FOLFIRI or XELIRI.
Adjuverende behandling af patienter med stadium III kolonkræft anbefales i en periode på 6 måneder.
Adjuvant treatment in patients with stage III colon cancer is recommended for a duration of 6 months.
Da dette lægemiddel indeholder vandfri lactose som hjælpestof, bør patienter med arvelig galactoseintolerans, en særlig form for hereditær lactasemangel (Total Lactase deficiency) eller glucose/galactosemalabsorption ikke anvende dette lægemiddel.
As this medicinal product contains anhydrous lactose as an excipient, patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Enzymerne, som er involverede i den katalytiske aktivering findes i tumorvæv, men også i normalt væv, om end i lavere koncentrationer.
The enzymes involved in the catalytic activation are found in tumour tissues but also in normal tissues, albeit usually at lower levels.
Den poolede analyse omfatter 3097 patienter, som blev behandlet med regimer, som indeholdt capecitabin, og 3074 patienter, som blev behandlet med regimer, som indeholdt 5-FU.
The pooled analysis includes 3097 patients treated with capecitabine-containing regimens and 3074 patients treated with 5-FU-containing regimens.
Desuden indtraf der i en 13-ugers undersøgelse atrofiske og degenerative forandringer i reproduktionsorganerne hos hanmus; forandringerne var dog reversible efter en stoffri periode (se pkt.
In addition, during a 13-week study, atrophic and degenerative changes occurred in reproductive organs of male mice; however these effects were reversible after a drug-free period (see section 4.6).
Accord Healthcare Limited, Sage house, 319 Pinner Road, Harrow HA1 4HF, Storbritannien Pharmacare Premium Limited, HHF 003, Hal Far Industrial Estate Birzebbugia, BBG 3000, Malta KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenien
Accord Healthcare Limited, Sage house, 319 Pinner Road, Harrow HA1 4HF, United Kingdom Pharmacare Premium Limited, HHF 003, Hal Far Industrial Estate Birzebbugia, BBG 3000, Malta KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
- for 1. linjebehandling af fremskreden ventrikelkræft i kombination med et platinbaseret regime (se pkt.
- first-line treatment of advanced gastric cancer in combination with a platinum based regimen (see section 5.1).
Der er ingen bivirkninger forbundet med at stoppe behandlingen med capecitabin.
There are no side-effects caused by stopping treatment with capecitabine.
Sikkerhedsprofilen for capecitabin-monoterapi i populationerne med metastatisk brystkræft, metastatisk kolorektalkræft og adjuverende kolonkræft er sammenlignelige.
The safety profiles of capecitabine monotherapy for the metastatic breast cancer, metastatic colorectal cancer and adjuvant colon cancer populations are comparable.
Tag ikke den glemte dosis.
Do not take the missed dose at all.
Der var en mindre stigning i plasmakoncentrationerne af capecitabin og en af metabolitterne (5'DFCR), men ingen virkning på de 3 hovedmetabolitter (5'DFUR, 5-FU og FBAL).
There was a small increase in plasma concentrations of capecitabine and one metabolite (5'-DFCR); there was no effect on the 3 major metabolites (5'-DFUR, 5-FU and FBAL).
XELIRI er blevet sammenlignet med 5-fluoruracil + irinotecan (FOLFIRI) hos patienter med metastatisk kolorektalkræft i tre randomiserede studier.
The XELIRI has been compared with 5-FU + irinotecan (FOLFIRI) in three randomised studies in patients with metastatic colorectal cancer.
Samlet responsrate var 49 % i XELIRI-armen og 48 % i FOLFIRI-armen (p = 0,76).
Overall response rate was 49% in the XELIRI and 48% in the FOLFIRI arm (p=0.76).
Studiet indeholdte to dele: En initial 2-arms del, i hvilken 634 patienter blev randomiseret i to forskellige behandlingsgrupper, inkluderende XELOX eller FOLFOX-4, og efterfølgende 2*2 design, i hvilken 1.401 patienter blev randomiseret til 4 forskellige behandlingsgrupper, inkluderende XELOX plus placebo, FOLFOX-4 plus placebo, XELOX plus bevacizumab og FOLFOX-4 plus bevacizumab.
The study contained two parts: an initial 2-arm part in which 634 patients were randomised to two different treatment groups, including XELOX or FOLFOX-4, and a subsequent 2x2 factorial part in which 1401 patients were randomised to four different treatment groups, including XELOX plus placebo, FOLFOX-4 plus placebo, XELOX plus bevacizumab, and FOLFOX-4 plus bevacizumab.
AUC0- værdierne (g•time/ml var 7,75; 7,24; 24,6; 2,03 og 36,3.
The AUC0- values in g•h/ml were 7.75, 7.24, 24.6, 2.03 and 36.3.
Nogle af bivirkningerne er reaktioner, som er almindeligt observeret med kombinationslægemidlet (f.eks. perifer sensorisk neuropati med docetaxel eller oxaliplatin, hypertension set med bevacizumab); en forværring ved capecitabin-behandlingen kan dog ikke udelukkes.
Some of the ADRs are reactions commonly seen with the combination medicinal product (e.g. peripheral sensory neuropathy with docetaxel or oxaliplatin, hypertension seen with bevacizumab); however an exacerbation by capecitabine therapy cannot be excluded.
For patienter med delvis DPD-mangel (fx med heterozygote mutationer i DPYD-genet), og hvor fordelene af Ecansya anses for at opveje risikoen (under hensyntagen til egnetheden af et alternativt ikke-fluorpyrimidin kemoterapeutisk regime), gælder, at de skal behandles med yderste forsigtighed og hyppig monitorering med dosisjustering i henhold til toksicitet.
For patients with partial DPD deficiency (such as those with heterozygous mutations in the DPYD gene) and where the benefits of Ecansya are considered to outweigh the risks (taking into account the suitability of an alternative non-fluoropyrimidine chemotherapeutic regimen), these patients must be treated with extreme caution and frequent monitoring with dose adjustment according to toxicity.
Capecitabin metaboliseres først af hepatisk carboxylesterase til 5'-DFCR, som derefter omdannes til 5'-DFUR af cytidindeaminase, som fortrinsvis findes i leveren og i tumorvæv.
Capecitabine is first metabolised by hepatic carboxylesterase to 5'-DFCR, which is then converted to 5-DFUR by cytidine deaminase, principally located in the liver and tumour tissues.
Der er holdepunkter for at metabolismen af 5-FU i den anabolske pathway blokerer metyleringen af desoxyuridylsyre til thymidylssyre og derved interfererer med desoxyribonukleinsyresyntesen (DNA).
There is evidence that the metabolism of 5-FU in the anabolic pathway blocks the methylation reaction of deoxyuridylic acid to thymidylic acid, thereby interfering with the synthesis of deoxyribonucleic acid (DNA).
Dehydrering kan forårsage akut nyreinsufficiens særligt hos patienter med eksisterende kompromitteret nyrefunktion, eller når capecitabin gives samtidigt med lægemidler med kendt nefrotoksisk effekt.
Dehydration may cause acute renal failure, especially in patients with pre-existing compromised renal function or when capecitabine is given concomitantly with known nephrotoxic medicinal products.
Kontakt din læge med det samme, hvis du er bekymret for en eller flere af bivirkningerne, eller hvis du får bivirkninger, som ikke fremgår af denne indlægsseddel (se punkt 4 Bivirkninger).
Contact your doctor immediately if you are concerned about any of the side effects or if you notice any additional side effects not listed in the leaflet (see section 4 Possible side effects).
Der bør udvises forsigtighed, når capecitabin administreres samtidig med 2C9-substrater (fx phenytoin).
Care should be exercised when capecitabine is co-administered with 2C9 substrates (e.g., phenytoin).
Capecitabin er et non-cytotoksisk fluorpyrimidincarbamat, som virker som en oral administreret prækursor for det cytotoksiske 5- fluorouracil (5-FU).
Capecitabine is a non-cytotoxic fluoropyrimidine carbamate, which functions as an orally administered precursor of the cytotoxic moiety 5-fluorouracil (5-FU).
Dosisjusteringer under behandlingen
Posology adjustments during treatment
I humane cancerxenotransplantationsmodeller har capecitabin vist en synergistisk effekt i kombination med docetaxel, som kan være relateret til docetaxels opregulering af thymidinfosforylase.
In human cancer xenograft models capecitabine demonstrated a synergistic effect in combination with docetaxel, which may be related to the upregulation of thymidine phosphorylase by docetaxel.
Reduceret dosis
Reduced dose
Spørg apotekspersonalet hvordan du skal bortskaffe medicinrester.
Ask your pharmacist how to throw away medicines you no longer use.
Nedsat visual skarphed, Diplopi
Visual acuity reduced, Diplopia
Aluminium/aluminium- eller PVC/PVdC/aluminium-blistere indeholdende 10 filmovertrukne tabletter.
Aluminium/aluminium or PVC/PVdC/aluminium blister containing 10 film-coated tablets.
Yderligere information om dette lægemiddel findes på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Efter oral administration af 825 mg/m2 capecitabin to gange dagligt i 14 dage, havde patienter af japansk oprindelse (n=18) omkring 36 % lavere Cmax og 24 % lavere AUC for capecitabin end patienter af kaukasisk oprindelse (n=22).
Following oral administration of 825 mg/m2 capecitabine twice daily for 14 days, Japanese patients (n=18) had about 36% lower Cmax and 24% lower AUC for capecitabine than Caucasian patients (n=22).
Ældre.
Elderly.
Dosis skal reduceres om nødvendigt (se pkt.
Dose reduction should be applied as necessary (see section 4.2).
Baseret på populationsfarmakokinetiske analyser, som omfattede patienter i mange aldre (27 - 86 år), og som omfattede 234 (46 %) patienter, som var mindst 65 år, spillede alderen ingen rolle for farmakokinetikken af 5'-DFUR og 5-FU.
Based on the population pharmacokinetic analysis, which included patients with a wide range of ages (27 to 86 years) and included 234 (46%) patients greater or equal to 65, age has no influence on the pharmacokinetics of 5'-DFUR and 5-FU.
Systemorgan-klasse Meget almindelig
Body System Very Common
Følgende kovarianter var statistisk signifikant associeret med en faldende risiko for udviklingen af diarré: øget kumulativ capecitabin-dosis (0,1 *kg) og med stigende relativ dosisintensitet i de første seks uger.
The following covariates were statistically significantly associated with a decreased risk of developing diarrhoea: increasing cumulative capecitabine dose (0.1*kg) and increasing relative dose intensity in the first six weeks.
Ved dehydrering af grad 2 (eller højere), bør behandlingen med capecitabin straks seponeres, og dehydreringen korrigeres.
If grade 2 (or higher) dehydration occurs, capecitabine treatment should be immediately interrupted and the dehydration corrected.
Det skal du vide, før du begynder at tage Ecansya 3.
What you need to know before you take Ecansya 3.
Nogle af disse bivirkninger er mere almindelige, når capecitabin bruges sammen med anden kræftmedicin.
Some of these side effects are more common when capecitabine is used with other medicines for the treatment of cancer.
For de toksiciteter, for hvilke den behandlende læge anser det for usandsynligt, at disse kan udvikle sig til at blive alvorlige eller livstruende, som f.eks. alopeci, smagsændringer og negleforandringer, kan behandlingen fortsættes med uændret dosis uden dosisreduktion eller behandlingsafbrydelse.
For those toxicities considered by the treating physician to be unlikely to become serious or life-threatening, e.g. alopecia, altered taste, nail changes, treatment can be continued at the same dose without reduction or interruption.
Behandling med brivudin kan initieres 24 timer efter sidste dosis af capecitabin.
Treatment with brivudine can be started 24 hours after the last dose of capecitabine.
Dosisjustering for næste serie/dosis (% af begyndelsesdosis)
Toxicity grades* Dose changes within a treatment cycle Dose adjustment for next cycle/dose (% of starting dose)
Capecitabin i kombinationsbehandling
Capecitabine in combination therapy
Oxaliplatin på dag 1, hver 2. uge Leucovorin på dag 1 og 2, hver 2.
Oxaliplatin on Day 1, every 2 weeks Leucovorin on Days 1 and 2, every 2 weeks
Samtidig anvendelse af allopurinol og capecitabin bør undgås.
Concomitant use of allopurinol with capecitabine should be avoided.
Du må ikke tage brivudin (et lægemiddel mod virus til behandling af helvedesild eller skoldkopper) samtidig med du får capecitabin-behandling (dette gælder også perioder, hvor du holder pause og ikke tager capecitabin tabletter).
You must not take brivudine (an anti-viral medicine for the treatment of shingles or chickenpox) at the same time as capecitabine treatment (including during any rest periods when you are not taking any capecitabine tablets).
Dehydrering
Dehydration.
For termer markeret med ”+” er hyppigheden baseret på bivirkninger af grad 3-4.
For terms marked with a “+”, the frequency count was based on grade 3-4 ADRs.
Patienter, som tager phenytoin og capecitabin samtidigt, skal kontrolleres regelmæssigt mht. stigninger i phenytoin-plasmakoncentrationerne.
Patients taking phenytoin concomitantly with capecitabine should be regularly monitored for increased phenytoin plasma concentrations.
Ecansya indeholder: - Aktivt stof: capecitabin.
What Ecansya contains - The active substance is capecitabine.
Der er set interaktion mellem allopurinol og 5-FU, med mulig nedsat effekt af 5-FU.
Allopurinol: interactions with allopurinol have been observed for 5-FU; with possible decreased efficacy of 5-FU.
Bivirkningerne er anført i passende frekvensgruppering ud fra den overordnede hyppighed i den samlede analyse.
ADRs are added to the appropriate frequency grouping according to the overall incidence from the pooled analysis.
FOLFIRI plus bevacizumab (arm-A, n=167) eller XELIRI plus bevacizumab (arm-B, n=166).
Patients were randomised to receive either FOLFIRI plus bevacizumab (Arm-A, n=167) or XELIRI plus bevacizumab (Arm-B, n-166).
I henhold til immunohistokemiske studier synes thymidinfosforylase hovedsageligt lokaliseret i stromale tumorceller.
According to immunohistochemical studies, thymidine phosphorylase appears to be in large part localised in tumour stromal cells.
I denne undersøgelse blev 627 patienter med metastatisk kolorektalkræft, som tidligere havde fået behandling med irinotecan i kombination med fluorpyrimidin som 1. linjebehandling, randomiseret til behandling med XELOX eller FOLFOX-4.
In this trial, 627 patients with metastatic colorectal carcinoma who have received prior treatment with irinotecan in combination with a fluoropyrimidine regimen as first line therapy were randomised to treatment with XELOX or FOLFOX-4.
Dosisjusteringer for særlige populationer:
Posology adjustments for special populations
Brivudin må ikke administreres samtidig med capecitabin.
Brivudine must not be administered concomitantly with capecitabine.
Hvis der ikke ses toksicitet hos patienter  60 år, som behandles med en nedsat initialdosis af capecitabin i kombination med docetaxel, kan capecitabin-dosis med forsigtighed øges til 1.250 mg/m2 to gange dagligt.
If no toxicity is observed in patients 60 years of age treated with a reduced capecitabine starting dose in combination with docetaxel, the dose of capecitabine may be cautiously escalated to 1250 mg/m2 twice daily.
Der skal være en periode på mindst 4 uger mellem endt behandling med brivudin og initieringen af capecitabinbehandling.
There must be at least a 4-week waiting period between end of treatment with brivudine and start of capecitabine therapy.
Oxaliplatin på dag 1, hver 3. uge Capecitabin oral to gange daglig i 2 uger (efterfulgt af 1 uge uden behandling)
Oxaliplatin on Day 1, every 3 weeks Capecitabine oral twice daily for 2 weeks (followed by 1 week offtreatment)
Udover dette kan Ecansya, når det anvendes alene, have følgende meget almindelige bivirkninger, som kan påvirke flere end 1 ud af 10 personer: - mavesmerter - udslæt, tør eller kløende hud - træthed - appetitløshed
In addition to the above, when Ecansya is used alone, very common side effects, which may affect more than 1 in 10 people are: - abdominal pain - rash, dry or itchy skin - tiredness - loss of appetite (anorexia)
cisplatin, irinotecan) - lægemidler til behandling af folsyremangel.
cisplatin, irinotecan), - medicines used to treat folic acid deficiency.
Hypo- eller hyperkalcæmi
Hypo- or hypercalcaemia.
Hvis der optræder grad 2 eller 3 af hånd- og fodsyndrom skal behandlingen med capecitabin afbrydes indtil symptomerne forsvinder eller er aftaget i intensitet til grad 1.
If grade 2 or 3 hand-foot syndrome occurs, administration of capecitabine should be interrupted until the event resolves or decreases in intensity to grade 1.
Frekvensen af den heterozygote DPYD*2A genotype i DPYD genet hos kaukasiske patienter er omkring 1% (1,1% for c.2846A>T, 2,6-6,3% for c.1236G>A/HapB3 varianter og 0,07 til 0,1% for c.1679T>G).
The frequency of the heterozygous DPYD*2A genotype in the DPYD gene in Caucasian patients is around 1%, 1.1% for c.2846A>T, 2.6-6.3% for c.1236G>A/HapB3 variants and 0.07 to 0.1% for c.1679T>G.
Ecansya-dosisberegninger
Ecansya dose calculations
Hvis du holder op med at tage Ecansya
If you stop taking Ecansya
Der blev set kardiovaskulær toksicitet (f.eks. forlængelse af PR- og QT-intervallet) hos cynomolgusabe efter intravenøs administration (100 mg/kg), men ikke efter gentagen oral dosering (1.379 mg/m2/dag).
Cardiovascular toxicity (e.g. PR- and QT-interval prolongation) was detectable in cynomolgus monkeys after intravenous administration (100 mg/kg) but not after repeated oral dosing (1379 mg/m2/day).
Efter oral administration af capecitabin til patienter med kolorektalkræft var forholdet mellem koncentrationen af 5-FU i de kolorektale tumorer og i de tilstødende væv 3,2 (spændvidde: 0,9 - 8,0).
Following oral administration of capecitabine to patients with colorectal cancer, the ratio of 5-FU concentration in colorectal tumours to adjacent tissues was 3.2 (ranged from 0.9 to 8.0).